|
1
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and manag-ement of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wan Z, Zhu Z, Wang P, Xu X, Ma T, Li H, Li
L, Qian F and Gu W: Targeting focal adhesion kinase in lung
diseases: Current progress and future directions. Biomolecules.
15:12332025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mangang KN and Rao GSNK: Lung cancer
biomarkers. Clin Chim Acta. 580:1207072026. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Campos-Carrillo A, Weitzel JN, Sahoo P,
Rockne R, Mokhnatkin JV, Murtaza M, Gray SW, Goetz L, Goel A,
Schork N and Slavin TP: Circulating tumor DNA as an early cancer
detection tool. Pharmacol Ther. 207:1074582020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu F, Fan J, He Y, Xiong A, Yu J, Li Y,
Zhang Y, Zhao W, Zhou F, Li W, et al: Single-cell profiling of
tumor heterogeneity and the microenvironment in advanced non-small
cell lung cancer. Nat Commun. 12:25402021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brosnan EM, Weickhardt AJ, Lu X, Maxon DA,
Barón AE, Chonchol M and Camidge DR: Drug-induced reduction in
estimated glomerular filtration rate in patients with ALK-positive
non-small cell lung cancer treated with the ALK inhibitor
crizotinib. Cancer. 120:664–674. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin PP: Integrated EpCAM-independent
subtraction enrichment and iFISH strategies to detect and classify
disseminated and circulating tumors cells. Clin Transl Med.
4:382015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin PP, Gires O, Wang DD, Li L and Wang H:
Comprehensive in situ co-detection of aneuploid circulating
endothelial and tumor cells. Sci Rep. 7:97892017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin PP: Aneuploid circulating
tumor-derived endothelial cell (CTEC): A novel versatile player in
tumor neovascularization and cancer metastasis. Cells. 9:15392020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lei Y, Sun N, Zhang G, Liu C, Lu Z, Huang
J, Zhang C, Zang R, Che Y, Mao S, et al: Combined detection of
aneuploid circulating tumor-derived endothelial cells and
circulating tumor cells may improve diagnosis of early stage
non-small-cell lung cancer. Clin Transl Med. 10:e1282020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Hong Y, Wang L, Hu W, Tian G, Wu
D, Wang Y, Dai L, Zhang Z, Yang Y and Fang J: Aneuploid subtypes of
circulating tumor cells and circulating tumor-derived endothelial
cells predict the overall survival of advanced lung cancer. Front
Oncol. 13:8290542023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Liu Y, Zhang L, Tong L, Gao Y, Hu
F, Lin PP, Li B and Zhang T: Vimentin expression in circulating
tumor cells (CTCs) associated with liver metastases predicts poor
progression-free survival in patients with advanced lung cancer. J
Cancer Res Clin Oncol. 145:2911–2920. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, Liu Y, Zhang Z, Lu B, Gao Y, Tong
L, Hu M, Lin PP, Li B and Zhang T: Post-therapeutic circulating
tumor cell-associated white blood cell clusters predict poor
survival in patients with advanced driver gene-negative non-small
cell lung cancer. BMC Cancer. 23:5782023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu JJ, Xiao W, Dong SL, Liang HF, Zhang
ZW, Zhang BX, Huang ZY, Chen YF, Zhang WG, Luo HP, et al: Effect of
surgical liver resection on circulating tumor cells in patients
with hepatocellular carcinoma. BMC Cancer. 18:8352018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Zhang L, Tan J, Zhang Z, Liu Y, Hu
X, Lu B, Gao Y, Tong L, Liu Z, et al: Longitudinal detection of
subcategorized CD44v6+ CTCs and circulating tumor
endothelial cells (CTECs) enables novel clinical stratification and
improves prognostic prediction of small cell lung cancer: A
prospective, multi-center study. Cancer Lett. 571:2163372023.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rahbari NN, Schölch S, Bork U, Kahlert C,
Schneider M, Rahbari M, Büchler MW, Weitz J and Reissfelder C:
Prognostic value of circulating endothelial cells in metastatic
colorectal cancer. Oncotarget. 8:37491–37501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhong X, Zhang H, Zhu Y, Liang Y, Yuan Z,
Li J, Li J, Li X, Jia Y, He T, et al: Circulating tumor cells in
cancer patients: Developments and clinical applications for
immunotherapy. Mol Cancer. 19:152020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Han T, Zhang J, Xiao D, Yang B, Chen L,
Zhai C, Ding F, Xu Y, Zhao X and Zhao J: Circulating tumor-derived
endothelial Cells: An effective biomarker for breast cancer
screening and prognosis prediction. J Oncol. 2022:52474232022.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Y, Yuan D, Ye W, Lv T and Song Y:
Prognostic value of circulating endothelial cells in non-small cell
lung cancer patients: A systematic review and meta-analysis. Transl
Lung Cancer Res. 4:610–618. 2015.PubMed/NCBI
|
|
22
|
Zhang J, Wang HT and Li BG: Prognostic
significance of circulating tumor cells in small-cell lung cancer
patients: A meta-analysis. Asian Pac J Cancer Prev. 15:8429–8433.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bhakdi SC, Suriyaphol P, Thaicharoen P,
Grote STK, Komoltri C, Chaiyaprasithi B and Charnkaew K: Accuracy
of tumour-associated circulating endothelial cells as a screening
biomarker for clinically significant prostate cancer. Cancers
(Basel). 11:10642019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xing C, Li Y, Ding C, Wang S, Zhang H,
Chen L, Li P and Dai M: CD44+ circulating tumor endothelial cells
indicate poor prognosis in pancreatic ductal adenocarcinoma after
radical surgery: A pilot study. Cancer Manag Res. 13:4417–4431.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yuan DM, Zhang Q, Lv YL, Ma XQ, Zhang Y,
Liu HB and Song Y: Predictive and prognostic significance of
circulating endothelial cells in advanced non-small cell lung
cancer patients. Tumour Biol. 36:9031–9037. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang Z, Zhou J, Li L, Liao S, He J, Zhou
S and Zhou Y: Pericytes in the tumor microenvironment. Cancer Lett.
556:2160742023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang C, Bork U, Schölch S, Kulu Y,
Kaderali L, Bolstorff UL, Kahlert C, Weitz J, Rahbari NN and
Reissfelder C: Postoperative course and prognostic value of
circulating angiogenic cytokines after pancreatic cancer resection.
Oncotarget. 8:72315–72323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin D, Shen L, Luo M, Zhang K, Li J, Yang
Q, Zhu F, Zhou D, Zheng S, Chen Y and Zhou J: Circulating tumor
cells: Biology and clinical significance. Signal Transduct Target
Ther. 6:4042021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ke H, Kao S, van Zandwijk N, Rasko JEJ and
Yeo D: Circulating tumor cell detection may offer earlier diagnosis
in patients suspected of asbestos-related lung cancer. Lung Cancer.
192:1078292024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dai CS, Mishra A, Edd J, Toner M,
Maheswaran S and Haber DA: Circulating tumor cells: Blood-based
detection, molecular biology, and clinical applications. Cancer
Cell. 43:1399–1422. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Felden J, Schulze K, Krech T, Ewald F,
Nashan B, Pantel K, Lohse AW, Riethdorf S and Wege H: Circulating
tumor cells as liquid biomarker for high HCC recurrence risk after
curative liver resection. Oncotarget. 8:89978–89987. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pereira-Veiga T, Schneegans S, Pantel K
and Wikman H: Circulating tumor cell-blood cell crosstalk: Biology
and clinical relevance. Cell Rep. 40:1112982022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gootjes EC, Kraan J, Buffart TE, Bakkerus
L, Zonderhuis BM, Verhoef C, Verheul HMW and Sleijfer AS:
CD276-positive circulating endothelial cells do not predict
response to systemic therapy in advanced colorectal cancer. Cells.
9:1242020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu HH, Liu YT, Feng Y, Zhang LN, Zhang
TM, Dong GL, Xing PY, Wang HY, Shi YK and Hu XS: Circulating tumor
cells (CTCs)/circulating tumor endothelial cells (CTECs) and their
subtypes in small cell lung cancer: Predictors for response and
prognosis. Thorac Cancer. 12:2749–2757. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luo S, Ou Y, Zheng T, Jiang H, Wu Y, Zhao
J and Zhang Z: optimal strategy for colorectal cancer patients'
diagnosis based on circulating tumor cells and circulating tumor
endothelial cells by subtraction enrichment and
immunostaining-fluorescence in situ hybridization combining with
CEA and CA19-9. J Oncol. 2021:15174882021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang L, Liu Z, Zhang Y, Wu Z, Liu Y and
Wang Z: The predictive value and clinical application of measuring
circulating endothelial progenitor cells in lung adenocarcinoma. J
Cardiothorac Surg. 21:3522026. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang L, Zhang X, Liu Y, Zhang T, Wang Z,
Gu M, Li Y, Wang DD, Li W and Lin PP: PD-L1+ aneuploid
circulating tumor endothelial cells (CTECs) exhibit resistance to
the checkpoint blockade immunotherapy in advanced NSCLC patients.
Cancer Lett. 469:355–366. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Naito T, Tanaka F, Ono A, Yoneda K,
Takahashi T, Murakami H, Nakamura Y, Tsuya A, Kenmotsu H, Shukuya
T, et al: Prognostic impact of circulating tumor cells in patients
with small cell lung cancer. J Thorac Oncol. 7:512–519. 2012.
View Article : Google Scholar : PubMed/NCBI
|
